Changes of hemostatic molecular markers after gynecological surgery

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 4, 2000, Pages 197-201

  Noda, Kazuhiko ^a   Noda, Naomi ^a   Okugawa, Toshiharu ^a   Yanoh, Kenji ^a   Ito, Masazumi ^a   Toyoda, Nagayasu ^a   Wada, Hideo ^a,b   Shiku, Hiroshi ^b   Nobori, Tsutomu ^a   Yamada, Norikazu ^c   Nakano, Takeshi ^c   Gabazza, Esteban C ^d   Kumeda, Kouzou ^e   Kato, Hisao ^f  

^a Department of Obstetrics and Gynecology ^*  (United States)

^b Second Department of Internal Medicine   (United States)

^c First Department of Internal Medicine   (United States)

^d MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Chemo Sero Therapeutic Research Institute   (Japan)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Cancer; Hemostatic marker; Myoma; Pulmonary embolism; Surgery

Indexed keywords

ANTITHROMBIN; D DIMER; FIBRIN; FIBRINOGEN; PROTEIN C;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CLINICAL ARTICLE; GYNECOLOGIC SURGERY; HEMOSTASIS; HUMAN; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; OPERATION DURATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTITHROMBINS; BIOLOGICAL MARKERS; ENDOMETRIAL NEOPLASMS; FEMALE; GENITAL NEOPLASMS, FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HEMOSTATICS; HUMANS; MIDDLE AGED; NEOPLASMS; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; PROTEIN C; PULMONARY EMBOLISM; RISK FACTORS; THROMBOSIS; TIME FACTORS;

EID: 0034548638     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600403     Document Type: Article

References (32)

1. Deficiency of protein C in congenital thrombotic disease
2. Familial protein S deficiency is associated with recurrent thrombosis
3. Antithrombin III deficiency in a Dutch family
4. The regulation of natural anticoagulant pathways
5. Increased activated protein C-protein C inhibitor complex levels in patients with pulmonary embolism
6. Recurrent venous thromboembolism in patients with a partial deficiency of protein S
7. Natural anticoagulant mechanisms
8. Determination of human thrombin-antithrombin III complex in plasma with an enzyme-linked immunosorbent assay
9. An immunoassay for human D dimer using monoclonal antibodies
10. Monoclonal antibodies to discrete regions in α2-plasmin inhibitor
11. Increased plasma soluble fibrin monomer levels in patients with disseminated intravascular coagulation
12. Disseminated intravascular coagulation and related syndromes: A clinical review
13. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways
14. Hemostatic abnormalities in patients with pulmonary embolism compared with that in deep vein thrombosis
15. Tissue factor revisited
16. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation
17. Changes in plasma tissue factor pathway inhibitor levels during the clinical course of disseminated intravascular coagulation
18. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction
19. Anticoagulant activity in cell homogenate of adult T cell leukemia
20. Prevention of venous thromboembolism
21. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
22. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
23. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
24. Mutation in blood coagulation factor V associated with resistance to activated protein C
25. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C
26. Plasma level of IL-1 β in disseminated intravascular coagulation
27. Plasma level of tumor necrosis factor in disseminated intravascular coagulation
28. Increased plasma level of interleukin-6 in disseminated intravascular coagulation
29. Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun
30. Regulation of the extrinsic pathway system in health and disease: The role of factor VIIa and tissue factor pathway inhibitor
31. Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thrombocytopenic purpura
32. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries